Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06930794 | A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive(KUNPENG-3) | recruiting | Phase 3 | 300 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07561567 | Feasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device(E20241186) | recruiting | — | 50 | Tianjin Medical University Cancer Institute and Hospital |
| 1 |
| May 1, 2026 |
| clinicaltrials |
| NCT07563205 | Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer(OMAE) | recruiting | — | 100 | GFPC InvestigationOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05191485 | Shared Decision Making in Patients With Lung Cancer | recruiting | — | 190 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05398094 | Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy(MERIT-lung) | recruiting | Phase 2 | 19 | Fundación GECPOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07279402 | TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50% | recruiting | — | 150 | Antalya Training and Research HospitalOTHER_GOV | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07309952 | Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC(SACTION 2501) | recruiting | Phase 2 | 28 | Yang HongOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05122806 | Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC(BIOEXALK) | recruiting | N/A | 100 | Groupe Francais De Pneumo-CancerologieOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06247826 | Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion(RESAMEX) | recruiting | N/A | 30 | Groupe Francais De Pneumo-CancerologieOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06620835 | Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib(OPTALK) | recruiting | Phase 2 | 45 | Groupe Francais De Pneumo-CancerologieOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06646471 | PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies(PROMETHEE) | recruiting | Phase 4 | 500 | GFPC InvestigationOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05168566 | Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 2 | 99 | Teligene USINDUSTRY | 2 | Apr 28, 2026 | clinicaltrials |
| NCT05528458 | Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma | recruiting | Phase 2 | 59 | Samsung Medical CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05522660 | Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer(USZ-STRIKE) | recruiting | Phase 3 | 180 | ETOP IBCSG Partners FoundationNETWORK | 5 | Apr 27, 2026 | clinicaltrials |
| NCT07243132 | Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)(LUNGEVITY) | recruiting | — | 1,000 | GFPC InvestigationOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07439094 | A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 140 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06010329 | A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC | recruiting | Phase 2 | 66 | Teligene USINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06687408 | Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques | recruiting | — | 450 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06816992 | ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC | recruiting | Phase 1 | 76 | ORIC PharmaceuticalsINDUSTRY | 3 | Apr 24, 2026 | clinicaltrials |
| NCT07548060 | A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy(TROP-LUNG) | recruiting | Phase 2 | 25 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT06623656 | Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC | recruiting | Phase 2 | 112 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05482568 | A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 324 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06326411 | A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors(NST-628) | recruiting | Phase 1 | 230 | Nested Therapeutics, IncINDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT06330038 | Anesthesia and Non-small Cell Lung Cancer Recurrence(GASTIVA) | recruiting | Phase 4 | 5,384 | Samsung Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06838273 | A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04) | recruiting | Phase 3 | 720 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07276789 | Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer | recruiting | Phase 2 | 35 | Integro TheranosticsINDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07323641 | Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer | recruiting | Phase 2 | 60 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07538947 | Real-Time Imaging to Improve Lung Cancer Diagnosis : Comparing Confocal Laser Endomicroscopy (CLE) With Standard Biopsy for Quicker and Safer Detection of Non-Small Cell Lung Cancer(SCORACLE) | recruiting | — | 70 | Central Hospital, Nancy, FranceOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07535463 | A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 53 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02468024 | JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer(STABLE-MATES) | recruiting | Phase 3 | 272 | University of Texas Southwestern Medical CenterOTHER | 4 | Apr 16, 2026 | clinicaltrials |
| NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy(PSI-Immune) | recruiting | Phase 2 | 880 | Diwakar DavarOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03948100 | Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers | recruiting | N/A | 400 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06688422 | Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy(INSPIRE-CRT) | recruiting | N/A | 100 | The Cooper Health SystemOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07020065 | Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% | recruiting | Phase 2 | 156 | Swiss Cancer InstituteOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07288034 | Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial | recruiting | Phase 2 | 535 | City of Hope Medical CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06141070 | Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease(ANDROMEDA) | recruiting | Phase 3 | 240 | Vastra Gotaland RegionOTHER_GOV | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06992739 | Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)(PROTECT-2) | recruiting | Phase 2 | 49 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07528274 | Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07529145 | Cardiopulmonary Exercise Testing in Lung Cancer Patients Before and During Oncological Treatment | recruiting | — | 90 | Medical University of BialystokOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04686305 | Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC(DL03) | recruiting | Phase 1 | 304 | AstraZenecaINDUSTRY | 19 | Apr 13, 2026 | clinicaltrials |
| NCT04937283 | Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm | recruiting | N/A | 690 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06564324 | A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients | recruiting | Phase 3 | 194 | Nuvation Bio Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06660407 | Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer | recruiting | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | recruiting | Phase 1 / Phase 2 | 191 | Tango Therapeutics, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06865339 | Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer(TRIPL) | recruiting | Phase 2 | 76 | Montefiore Medical CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07195084 | To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer(HyPROS-LC) | recruiting | N/A | 12 | Anhui Provincial Cancer HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05445791 | Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations(METLUNG) | recruiting | Phase 3 | 312 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 9, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 1, 2026source: clinicaltrials